Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas
A Phase I/II Study Using Eflornithine (DFMO) and AMXT 1501 for Relapsed and Refractory Neuroblastoma, CNS Tumors, and Sarcomas
-
Clinical Trial Information
Trial Contact: Frankos, Marie; Jones, Jamie; Singh, Sarah H; Torrescano, Tanner
Trial Phone: 321-842-8738 ; 3218412008 ; 321.841.7561 ; 321-841-8271
-
IRB No: S24.087.07
Protocol Abbrev: BCC020
Principal Investigator: Jaime A. Carvajal, MD
Phase: Drug: Phase I
Age Group: Pediatric;Adult
ClinicalTrials.gov ID: NCT06465199
-
Objective
-Establish a recommended dose of AMXT 1501 in combination with DFMO for infusion
-Test the safety and tolerability of AMXT 1501 in combination with DFMO for infusion in patients with cancer
-To determine the activity of study treatments chosen based on:
-How each subject responds to the study treatment
-How long a subject lives without their disease returning/progressing
